XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 28, 2025
Dec. 31, 2024
Assets    
Cash and cash equivalents $ 1,343 $ 1,043
Short-term investments 13,641 19,434
Trade accounts receivable, net of allowance for doubtful accounts: 2025—$434; 2024—$438 14,260 11,463
Inventories 11,468 10,851
Current tax assets 3,855 3,314
Other current assets 2,358 4,253
Total current assets 46,924 50,358
Long-term investments 2,137 2,228
Property, plant and equipment, net of accumulated depreciation: 2025—$17,505; 2024—$16,483 18,880 18,393
Identifiable intangible assets, net [1] 51,324 55,411
Goodwill 69,101 68,527
Noncurrent deferred tax assets and other noncurrent tax assets 11,048 8,662
Other noncurrent assets 9,317 9,817
Total assets 208,731 213,396
Liabilities and Equity    
Short-term borrowings, including current portion of long-term debt: 2025—$4,247; 2024—$3,747 4,303 6,946
Trade accounts payable 5,024 5,633
Dividends payable 0 2,437
Income taxes payable 3,799 2,910
Accrued compensation and related items 3,036 3,838
Deferred revenues 924 1,511
Other current liabilities 19,509 19,720
Total current liabilities 36,596 42,995
Long-term debt 57,409 57,405
Pension and postretirement benefit obligations 2,157 2,115
Noncurrent deferred tax liabilities 2,467 2,122
Other taxes payable 3,401 6,112
Other noncurrent liabilities 13,605 14,150
Total liabilities 115,635 124,899
Commitments and Contingencies
Common stock 481 480
Additional paid-in capital 94,248 93,603
Treasury stock (115,011) (114,763)
Retained earnings 121,150 116,725
Accumulated other comprehensive loss (8,066) (7,842)
Total Pfizer Inc. shareholders’ equity 92,801 88,203
Equity attributable to noncontrolling interests 295 294
Total equity 93,096 88,497
Total liabilities and equity $ 208,731 $ 213,396
[1] The decrease is primarily due to amortization expense of $3.6 billion.